These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 1174223)
1. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol. Chan JC; Oldham SB; Holick MF; DeLuca HF JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223 [TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
3. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure. Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527 [TBL] [Abstract][Full Text] [Related]
4. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633 [TBL] [Abstract][Full Text] [Related]
5. Comparison of effects of 1 alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man. Brickman AS; Coburn JW; Friedman GR; Okamura WH; Massry SG; Norman AW J Clin Invest; 1976 Jun; 57(6):1540-7. PubMed ID: 932193 [TBL] [Abstract][Full Text] [Related]
6. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125 [TBL] [Abstract][Full Text] [Related]
7. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone. Birkenhäger-Frenkel DH; Pols HA; Zeelenberg J; Eijgelsheim JJ; Schot R; Nigg AL; Weimar W; Mulder PG; Birkenhäger JC J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799 [TBL] [Abstract][Full Text] [Related]
8. Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy. Fukushima M; Niki R; Ohkawa H; Shimizu T; Matsunaga I; Nakano H; Takagaki Y; Nishii Y; Okano K; Suda T Endocrinology; 1980 Jul; 107(1):328-33. PubMed ID: 6247140 [TBL] [Abstract][Full Text] [Related]
9. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Madsen S Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650 [No Abstract] [Full Text] [Related]
10. The kidney as an endocrine organ involved in the function of vitamin D. DeLuca HF Am J Med; 1975 Jan; 58(1):39-47. PubMed ID: 163578 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis. Kimura Y; Nakayama M; Kuriyama S; Watanabe S; Kawaguchi Y; Sakai O Clin Nephrol; 1991 Feb; 35(2):72-7. PubMed ID: 2019017 [TBL] [Abstract][Full Text] [Related]
12. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3. Voigts AL; Felsenfeld AJ; Llach F Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827 [TBL] [Abstract][Full Text] [Related]
14. [Intestinal absorption of Ca47 in chronic renal insufficiency before and after treatment with 1,25 dihydroxycholecalciferol]. Vattimo A Minerva Med; 1979 Dec; 70(54):3705-7. PubMed ID: 523001 [TBL] [Abstract][Full Text] [Related]
15. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy. Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961 [TBL] [Abstract][Full Text] [Related]
16. L-alpha-hydroxycholecalciferol treatment of adults with chronic renal failure. Madsen S; Olgaard K Acta Med Scand; 1976; 200(1-2):1-5. PubMed ID: 961464 [TBL] [Abstract][Full Text] [Related]
17. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues. Norman AW; Sergeev IN; Bishop JE; Okamura WH Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333 [TBL] [Abstract][Full Text] [Related]
18. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B Nephron; 1995; 71(3):254-83. PubMed ID: 8569975 [TBL] [Abstract][Full Text] [Related]
19. A possible direct effect of 24,25-dihydroxycholecalciferol on the parathyroid gland in patients with chronic renal failure. Christiansen C; Rødbro P; Naestoft J; Christensen MS Clin Endocrinol (Oxf); 1981 Sep; 15(3):237-42. PubMed ID: 6273028 [TBL] [Abstract][Full Text] [Related]
20. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy. Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]